Shares of other companies:
May 1, 2024 Inflation Persistence: No Fed Rate Cuts in Sight
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
3M Stock: Dividend Likely Cut In Half
May 1, 2024
Amazon Q1 Review: Best Of Big Tech Bunch
April 30, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
REGN Stock News and Mentions of Regeneron Pharmaceuticals, Inc. Stocktwits
Updated: May 2, 2024 (11:06)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Regeneron Pharmaceuticals Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Regeneron Pharmaceuticals, Inc. (REGN).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Regeneron Pharmaceuticals stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Regeneron Pharmaceuticals, Inc. (REGN)
May 2, 2024 (19:49) / "Benzinga" (by Vandana Singh)
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation - Regeneron Pharmaceuticals ( NASDAQ:REGN )
On Thursday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted EPS of $9.55, down 5% Y/Y, missing the consensus of $10.10. The company reported sales of $3.15 billion, missing the consensus of $3.22 billion. First quarter 2024 revenues decreased by 1%.
In Article Trend: Neutral
May 2, 2024 (14:30) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 15.96% on an annualized basis producing an average annual return of 23.84%. Currently, Regeneron Pharmaceuticals has a market capitalization of $100.69 billion.
In Article Trend: Somewhat-Bullish
May 2, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Regeneron ( REGN ) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
In Article Trend: Neutral
May 2, 2024 (11:15) / "Motley Fool" (by Prosper Junior Bakiny)
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
It pays to develop novel medicines for life-threatening illnesses.
In Article Trend: Somewhat-Bullish
May 2, 2024 (10:45) / "Investors Business Daily" (by Investor's Business Daily)
Regeneron Falls On Earnings Miss
Regeneron Stock Falls As Biotech Giant's Earnings Miss Estimates Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
May 2, 2024 (10:30) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
Regeneron Reports First Quarter 2024 Financial and Operating Results
TARRYTOWN, N.Y., May 02, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the first quarter of 2024 and provided a business update.
In Article Trend: Somewhat-Bullish
April 30, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight
The medical dynamometers market is predicted to surge owing to the rise in bone-related conditions like osteoporosis and arthritis, along with an uptick in sports injuries and the expanding elderly demographic.
In Article Trend: Bullish
April 30, 2024 (15:20) / "Zacks Commentary" (by Zacks Equity Research)
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
In Article Trend: Somewhat-Bullish
April 30, 2024 (14:31) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Benzinga's options scanner has just identified more than 16 option transactions on Regeneron Pharmaceuticals REGN, with a cumulative value of $427,360. Concurrently, our algorithms picked up 14 puts, worth a total of 418,490.
In Article Trend: Neutral
April 30, 2024 (12:47) / "Zacks Commentary" (by Zacks Equity Research)
Should You Consider Regeneron ( REGN ) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
In Article Trend: Somewhat-Bullish
April 30, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Regeneron Pharmaceuticals ( NASDAQ:REGN ) Rating Lowered to Buy at StockNews.com
Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a report issued on Tuesday.
In Article Trend: Somewhat-Bullish
April 29, 2024 (11:00) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
EYLEA® HD ( aflibercept ) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseases Long-term data and subgroup analyses from pivotal EYLEA HD clinical ...
In Article Trend: Neutral
April 26, 2024 (07:00) / "GlobeNewswire" (by Medigene AG)
Medigene AG reports Financial Results and Business Update for Q1 2024
Planegg/Martinsried, April 26, 2024. Medigene AG ( Medigene or the "Company", FSE: MDG1, Prime Standard ) , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024.
In Article Trend: Somewhat-Bullish
April 25, 2024 (15:21) / "Zacks Commentary" (by Zacks Equity Research)
Intellia ( NTLA ) to Report Q1 Earnings: What's in the Cards?
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
In Article Trend: Neutral
April 25, 2024 (12:44) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.
In Article Trend: Neutral
April 25, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Mammoth's proprietary ultracompact CRISPR-based gene editing platform and Regeneron's proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types TARRYTOWN, N.Y., April 25, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.
In Article Trend: Somewhat-Bullish
April 24, 2024 (19:51) / "Zacks Commentary" (by Mark Vickery)
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
In Article Trend: Somewhat-Bullish
April 24, 2024 (14:05) / "GlobeNewswire" (by Inc.)
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with ...
In Article Trend: Neutral
April 24, 2024 (12:30) / "Motley Fool" (by George Budwell)
2 Small-Cap Growth Stocks With Room to Run
These two small-cap growth stocks could be ready to run.
In Article Trend: Somewhat-Bullish
April 23, 2024 (11:30) / "GlobeNewswire" (by Ltd.)
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
- ARCALYST® ( rilonacept ) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $370 - $390 million -- Abiprubart Phase 2b trial in Sjögren's Disease planned to initiate in 2H 2024 -- Current operating ...
In Article Trend: Neutral
April 22, 2024 (21:54) / "GlobeNewswire" (by Inc.)
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy ( ASGCT )
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss ...
In Article Trend: Neutral
April 20, 2024 (06:18) / "Stocknews.com" (by Defense World Staff)
Regeneron Pharmaceuticals ( NASDAQ:REGN ) Lowered to Buy at StockNews.com
Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was downgraded by stock analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a note issued to investors on Saturday. REGN has been the topic of several other reports.
In Article Trend: Somewhat-Bullish
April 18, 2024 (21:03) / "Benzinga" (by Globe Newswire)
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. ( REGN ) - Regeneron Pharmaceuticals ( NASDAQ:REGN )
NEW YORK, April 18, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. ( "Regeneron" or the "Company" ) REGN. The investigation concerns whether Regeneron and/or certain of its officers have violated the ...
In Article Trend: Neutral
April 18, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry - Regeneron Pharmaceuticals ( NASDAQ:REGN )
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals REGN against its key competitors in the ...
In Article Trend: Neutral
April 18, 2024 (01:00) / "Benzinga" (by Globe Newswire)
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm - Regeneron Pharmaceuticals ( NASDAQ:REGN )
NEW YORK, April 17, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ( "Regeneron" or the "Company" ) REGN on behalf of Regeneron stockholders.
In Article Trend: Neutral
April 17, 2024 (17:00) / "Benzinga" (by Benzinga Insights)
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.99% on an annualized basis producing an average annual return of 22.65%. Currently, Regeneron Pharmaceuticals has a market capitalization of $99.62 billion.
In Article Trend: Somewhat-Bullish
April 17, 2024 (15:02) / "Zacks Commentary" (by Zacks Equity Research)
2seventy bio ( TSVT ) Rises More Than 50% in 3 Months: Here's Why
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
In Article Trend: Somewhat-Bullish
April 14, 2024 (05:44) / "Stocknews.com" (by Defense World Staff)
Regeneron Pharmaceuticals ( NASDAQ:REGN ) Stock Rating Upgraded by StockNews.com
Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a note issued to investors on Friday.
In Article Trend: Somewhat-Bullish
April 12, 2024 (17:54) / "Zacks Commentary" (by Zacks Equity Research)
Regeneron ( REGN ) Accused of Fraudulent Practices Related to Eylea
The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.
In Article Trend: Neutral
April 12, 2024 (16:38) / "Investors Business Daily" (by Investor's Business Daily)
Market Signals Mixed; Nvidia, Inflation, Iran In Focus: Weekly Review
Market Signals Mixed. Nvidia, Inflation, Iran In Focus: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
April 11, 2024 (18:09) / "Benzinga" (by Vandana Singh)
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug - Regeneron Pharmaceuticals ( NASDAQ:REGN )
The U.S. Justice Department has leveled allegations against Regeneron Pharmaceuticals REGN, accusing the company of manipulating Medicare's drug-pricing system for its macular degeneration drug, Eylea ( aflibercept ) .
In Article Trend: Somewhat-Bearish
April 11, 2024 (17:01) / "Investors Business Daily" (by Investor's Business Daily)
Are Regeneron's Legal Troubles - And 6-Week Slide - A Buying Opportunity?
Regeneron Stock Stumbles On DOJ Complaint. Is This A Buying Opportunity? Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (14:42) / "Investors Business Daily" (by DAVID SAITO-CHUNG)
Nvidia Rises To Trigger Entry As Indexes Sink Into Red
The stock market today lost opening gains and the major indexes moved lower in the first 45 minutes of trading. Nvidia staged a follow-on buy point. Chip shares led the upside, but enterprise software firms continued to cool. Bond prices continued to weaken, sending up yields and a near-term ...
In Article Trend: Neutral
April 11, 2024 (12:18) / "Investors Business Daily" (by ED CARSON)
Futures Fall Before Another Key Inflation Report
Stock Market Today: Dow Jones Futures Fall Ahead Of Inflation, Jobs Data. Nvidia, Microsoft Price Targets Raised Investor's Business Daily ...
In Article Trend: Neutral
April 9, 2024 (21:41) / "PR Newswire" (by DelveInsight Business Research)
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
The tissue banking market is experiencing a surge in demand due to several factors: the growing prevalence and occurrence of chronic illnesses, the expanding elderly population susceptible to such ailments, and the potential breakthroughs in treating cancers, blood disorders, immune conditions, ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (22:42) / "GlobeNewswire" (by Opthea Limited)
Opthea Appoints John Han, PharmD, as VP Medical Affairs
Brings extensive experience in retinal and ophthalmology diseases Brings extensive experience in retinal and ophthalmology diseases ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (21:41) / "PR Newswire" (by DelveInsight Business Research)
HPV16+ Cancer Treatment Market is Expected to Showcase Significant Growth by 2034, Assesses DelveInsight | Key Companies in the Market - Nykode Therapeutics, Roche, ISA Pharmaceuticals, Regeneron, Transgene
HPV16+ Cancer Treatment Market is Expected to Showcase Significant Growth by 2034, Assesses DelveInsight | Key ... PR ...
In Article Trend: Neutral
April 7, 2024 (20:00) / "Benzinga" (by Globe Newswire)
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y., April 07, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.
In Article Trend: Neutral
April 7, 2024 (20:00) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration ( FDA ) and European Medicines Agency ( EMA ) Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration ( FDA ) and European Medicines Agency ( ...
In Article Trend: Neutral
April 5, 2024 (11:00) / "Motley Fool" (by Prosper Junior Bakiny)
Should You Sell This Stock Following a Regulatory Roadblock?
It's not the first such obstacle this high-performing drugmaker has faced.
In Article Trend: Somewhat-Bullish
April 5, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (19:30) / "Benzinga" (by Benzinga Insights)
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 1.97% on an annualized basis producing an average annual return of 12.9%. Currently, Regeneron Pharmaceuticals has a market capitalization of $105.76 billion.
In Article Trend: Somewhat-Bullish
March 28, 2024 (17:45) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals REGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
March 28, 2024 (12:33) / "Zacks Commentary" (by Ekta Bagri)
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.
In Article Trend: Neutral
March 28, 2024 (12:00) / "Investors Business Daily" (by ALLISON GATLIN)
Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?
Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...
In Article Trend: Neutral
March 28, 2024 (12:00) / "Motley Fool" (by Prosper Junior Bakiny)
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the iShares Biotechnology ETF ( IBB ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:37) / "Zacks Commentary" (by Zacks Equity Research)
Regeneron's ( REGN ) Lymphoma Candidate Rejected by the FDA
Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
In Article Trend: Somewhat-Bullish
March 25, 2024 (15:50) / "Benzinga" (by Vandana Singh)
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Monday, the FDA issued complete response letters ( CRL ) to Regeneron Pharmaceuticals Inc's REGN Biologics License Application ( BLA ) for odronextamab in relapsed/refractory ( R/R ) follicular lymphoma ( FL ) and in R/R diffuse large B-cell lymphoma ( DLBCL ) , each after two or more lines of ...
In Article Trend: Neutral
March 25, 2024 (11:00) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
Regeneron Provides Update on Biologics License Application for Odronextamab
TARRYTOWN, N.Y., March 25, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration ( FDA ) has issued Complete Response Letters ( CRLs ) for the Biologics License Application ( BLA ) for odronextamab in ...
In Article Trend: Neutral
March 20, 2024 (20:15) / "GlobeNewswire" (by Alvotech)
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a summary of recent pipeline and corporate highlights.
In Article Trend: Neutral
March 20, 2024 (20:15) / "GlobeNewswire" (by Alvotech)
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
REYKJAVIK, Iceland, March 20, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a ...
In Article Trend: Neutral
March 20, 2024 (19:16) / "Benzinga" (by Benzinga Insights)
Regeneron Pharmaceuticals Unusual Options Activity For March 20 - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals REGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
March 19, 2024 (17:06) / "Zacks Commentary" (by Zacks Equity Research)
Intellia ( NTLA ) Begins Dosing in Phase III ATTR Amyloidosis Study
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
In Article Trend: Somewhat-Bullish
March 19, 2024 (04:57) / "The Financial Express" (by Health Desk)
Biomarkers becoming important for approval of amyotrophic lateral sclerosis therapies: GlobalData
The recently concluded AD/PD 2024 International Conference on Alzheimer's Disease ( AD ) and Parkinson's Disease ( PD ) focused on innovative approaches poised to revolutionize the treatment of amyotrophic lateral sclerosis ( ALS ) and the use of neurochemical biomarkers in ALS drug development.
In Article Trend: Somewhat-Bullish
March 15, 2024 (20:01) / "Benzinga" (by Benzinga Insights)
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (17:32) / "Zacks Commentary" (by Zacks Equity Research)
NewAmsterdam ( NAMS ) Doses Patient in HeFH Study, Shares Up
NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.
In Article Trend: Neutral
March 13, 2024 (12:51) / "Benzinga" (by Avi Kapoor)
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday - NVIDIA ( NASDAQ:NVDA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities raised the price target for Brown & Brown, Inc. BRO from $80 to $86.
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:32) / "Zacks Commentary" (by Zacks Equity Research)
Regeneron ( REGN ) Gets FDA Nod for Praluent Label Extension
Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
In Article Trend: Neutral
March 11, 2024 (21:15) / "Investing News Network" (by Melissa Pistilli)
Biotech ETFs to Watch
The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.
In Article Trend: Neutral
March 11, 2024 (11:00) / "GlobeNewswire" (by Inc.)
Praluent® ( alirocumab ) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia ( HeFH ) Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia ...
In Article Trend: Neutral
March 9, 2024 (10:52) / "Motley Fool" (by Keith Speights)
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be in store for all three of these drugmakers.
In Article Trend: Somewhat-Bullish
March 8, 2024 (13:15) / "Motley Fool" (by Prosper Junior Bakiny)
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:00) / "Benzinga" (by Globe Newswire)
EYLEA® HD ( aflibercept ) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration ( wAMD ) and Diabetic Macular Edema ( DME ) Published in The Lancet - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA® ( aflibercept ) Injection 2 mg with fixed 8-week dosing in patients with wAMD and DME in the first year
In Article Trend: Neutral
March 8, 2024 (12:00) / "GlobeNewswire" (by Regeneron Pharmaceuticals)
EYLEA® HD ( aflibercept ) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration ( wAMD ) and Diabetic Macular Edema ( DME ) Published in The Lancet
Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA® ( aflibercept ) Injection 2 mg with fixed 8-week dosing in patients with wAMD and DME in the first year ...
In Article Trend: Neutral
)
March 5, 2024 (01:53) / "Business Standard" (by Shivam Tyagi)
Stocks to watch: Tata Motors, M&M, IIFL Fin, NTPC, AU SFB, Godrej Agrovet | News on Markets
Stocks to watch: Tata Motors, M&M, IIFL Fin, NTPC, AU SFB, Godrej Agrovet Business Standard ...
In Article Trend: Neutral
)
March 4, 2024 (10:59) / "Business Standard" (by Anjali Singh)
Biocon Biologics gets green light to launch Yesafili biosimilar in Canada | Company News
Biocon Biologics gets green light to launch Yesafili biosimilar in Canada Business Standard ...
In Article Trend: Neutral
March 4, 2024 (05:51) / "Money Control"
Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada
The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea ( aflibercept ) injection, in the Canadian market, Biocon Biologics said in a regulatory filing.
In Article Trend: Neutral
March 4, 2024 (05:11) / "The Financial Express" (by FE Business)
Biocon Biologics secures Canada market entry date for YESAFILI
Biocon Biologics Ltd ( BBL ) , a globally integrated biosimilars company and a subsidiary of Biocon Ltd, on Monday announced the signing of a settlement with Bayer Inc. and Regeneron Pharmaceuticals, Inc.
In Article Trend: Neutral
March 4, 2024 (04:00) / "Business Standard" (by Capital Market)
Biocon Biologics set to introduce YESAFILI, a proposed biosimilar to EYLEA in Canadian market | Capital Market News
Biocon Biologics set to introduce YESAFILI, a proposed biosimilar to EYLEA in Canadian market Business Standard ...
In Article Trend: Neutral
Related stocks from Healthcare sector
Anavex Life Sciences Corp. (AVXL)
Stryker Corp. (SYK)
Blue Water Vaccines, Inc. (BWV)
Protagonist Therapeutics, Inc. (PTGX)
Adagio Therapeutics, Inc. (ADGI)
Virios Therapeutics, Inc. (VIRI)
Mesoblast Limited (MESO)
Galera Therapeutics, Inc. (GRTX)
Incyte Corp. (INCY)
Clever Leaves Holdings Inc. (CLVR)
This website uses cookies to ensure you get the best experience on our website